Head to head
KPV against LL-37
Two small immune peptides with opposite temperaments. KPV is an anti-inflammatory fragment of alpha-MSH; LL-37 is the main human cathelicidin, antimicrobial and pro-inflammatory, with a documented double-edged role in disease.
Column A
KPVKPV (lysine-proline-valine, alpha-MSH fragment)
A small anti-inflammatory tripeptide derived from alpha-MSH studied for gut inflammation and skin, mostly in preclinical models.
Column B
LL-37LL-37 (human cathelicidin antimicrobial peptide)
The main human cathelicidin antimicrobial peptide, central to innate immunity and wound healing, with a complex double-edged role in disease.
Side by side, on the facts we can check
| Attribute | KPV | LL-37 |
|---|---|---|
| Category | Healing & Recovery | Immune |
| FDA status | Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6 to recommend for compounding (July 2026); awaiting FDA rulemaking | Not FDA-approved; research peptide |
| Half-life | Short | Short |
| Molecular weight | 342.4 Da | 4,493.3 Da |
| Mechanism | Enters cells and suppresses pro-inflammatory NF-kB signaling, reducing inflammatory cytokine production. | Disrupts microbial membranes and modulates immune cell activity, wound repair, and inflammation. |
| Human studies cited | 0 | 2 |
| Legal status, US | Not approved; research use only | Not approved; research use only |
Frequently asked questions
What is the difference between KPV and LL-37?
KPV: A small anti-inflammatory tripeptide derived from alpha-MSH studied for gut inflammation and skin, mostly in preclinical models. LL-37: The main human cathelicidin antimicrobial peptide, central to innate immunity and wound healing, with a complex double-edged role in disease.
Which has stronger research evidence, KPV or LL-37?
This database does not grade compounds. It counts what was run in people: 0 of the 3 studies cited on the KPV profile were human work, against 2 of 4 for LL-37. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are KPV and LL-37 FDA-approved?
KPV: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6 to recommend for compounding (July 2026); awaiting FDA rulemaking. LL-37: Not FDA-approved; research peptide.
Related posts
Blog articles that cover KPV or LL-37, newest first.
- Healing & Recovery / Sep 8, 2026 / 8 minPeptides for Gut Health: BPC-157, KPV and Larazotide Ranked by Human Evidence
- Healing & Recovery / Sep 8, 2026 / 8 minGLOW vs KLOW vs Wolverine: What Is in Each Stack and What the Evidence Says, Ingredient by Ingredient
- Regulation / Sep 8, 2026 / 9 minFDA Peptide Status in 2026: The Category 2 Removals, the July Votes, and What Actually Changed
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.